Chelerythrine chloride
Cat. No.：YN310151
CAS No. ：3895-92-9
| 产品名称: | Chelerythrine chloride |
| CAS No.: | 3895-92-9 |
| Chemical Name: | 1,2-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridinium, monochloride |
| Synonyms: | 盐酸白屈菜红碱 |
| 分子量: | 383.82 |
| 分子式: | C₂₁H₁₈ClNO₄ |
| SMILES: | C[N+]1=CC2=C(C(OC)=CC=C2C3=C1C4=CC5=C(OCO5)C=C4C=C3)OC.[Cl-] |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Chelerythrine chloride 是一种有效，可渗透细胞的蛋白酶 C (protein kinase C) 抑制剂，能够抑制 PKC 活性，IC50值为 660 nM。Chelerythrine chloride 抑制Bcl-XL-Bak BH3肽结合，IC50为 1.5 μM，并从 Bcl-XL 取代了 Bax。Chelerythrine chloride 诱导细胞凋亡 (apoptosis) 和自噬 (autophagy)。 |
| IC50和靶点: | [{name:"PKC:660 nM (IC50)"},{name: "PKA:0.17 mM (IC50)"},{name: "TPK:0.1 mM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Herbert, J.M., Augereau, J.M., Gleye, J., et al.Chelerythrine is a potent and specific inhibitor of protein kinase CBiochem. Biophys. Res. Commun.172,993-999(1990)
Chan, S.L., Lee, M.C., Tan, K.O., et al.Identification of chelerythrine as an inhibitor of BclXL functionJ. Biol. Chem.278(23),20453-20456(2003)
Lee, S.K., Qing, W.G., Mar, W., et al.Angoline and chelerythrine, benzophenanthridine alkaloids that do not inhibit protein kinase CJ. Biol. Chem.273(31),19829-19833(1998)
Chmura, S.J., Dolan, M.E., Cha, A., et al.In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivoClin. Cancer Res.6,737-742(2012)
Yu, R., Mandlekar, S., Tan, T.H., et al.Activation of p38 and c-Jun N-terminal kinase pathways and induction of apoptosis by chelerythrine do not require inhibition of protein kinase CJ. Biol. Chem.275(13),9612-9619(2000)
Zhang, Z.F., Guo, Y., Zhang, J.b., et al.Induction of apoptosis by chelerythrine chloride through mitochondrial pathway and Bcl-2 family proteins in human hepatoma SMMC-7721 cellArch. Pharm. Res.34(5),791-800(2011)
